Nanoscope Submits Historical FDA Submission
Nanoscope Submits Historical FDA Submission
Nanoscope Therapeutics Inc., a biotechnology company focused on restoring vision for patients with retinal degenerative diseases, has initiated a rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for its lead therapy, MCO-010.
This marks a groundbreaking moment in the field: the first BLA submission for a gene-agnostic gene therapy targeting retinal disease. Unlike traditional approaches, MCO-010 is designed to benefit patients with retinitis pigmentosa (RP) regardless of the specific genetic mutation—an especially meaningful advancement for a disease tied to over 100 genes and more than 1,000 mutations.
This milestone underscores Nanoscope’s commitment to expanding access to innovative vision-restoring therapies for individuals with severe vision loss.
Powered By GrowthZone